fb_script

Immunotherapy found to be safe in pilot study of people with T1D

A pilot clinical trial in the US has found a new immunotherapy treatment to be safe in people with new onset type 1 diabetes (T1D).

After clinical presentation of T1D, beta cell loss continues progressively in most people until C-peptide levels, a marker of endogenous insulin production, is absent or present in very low levels. Despite intensive research efforts for more than 20 years, no therapy is currently available to prevent beta cell loss in T1D.

Read More

Importance of coeliac disease screening in people with T1D

A large multinational study including data from 52,721 participants have found international differences in prevalence of coeliac disease (CD) in those with T1D. Coeliac disease has a known association with T1D, and this study aimed to examine global differences in prevalence and management to improve understanding of the impact of both conditions.

Read More

Findings may improve prediction of T1D risk for prevention studies

TrialNet is an international collaborative network that aims to prevent, delay and reverse the progression of type 1 diabetes, involving United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand.

TrialNet in Australia/New Zealand is led by A/Prof John Wentworth at Walter & Eliza Hall Institute (WEHI) in collaboration with Prof Peter Colman AM.

Read More

T1DCRN awards $350K in seed funding grants

Two promising research projects have been targeted to receive contract seed funding grants, and will benefit from $350K in funding from the Type 1 Diabetes Clinical Research Network (T1DCRN), itself an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC).

Professor Peter Thorn (left) and Dr Vincent Ho

These two projects will explore new directions in curing and treating T1D and its complications. Read More

Tool could help predict lack of ‘honeymoon phase’ in young people with type 1 diabetes

A new study has developed a prediction tool to help clinicians predict which newly diagnosed children and adolescents are unlikely to experience a period of remission.

The remission phase, also called the honeymoon phase, is the period of time after clinical diagnosis of T1D where the body can make just enough insulin (“endogenous” insulin) to control blood glucose levels either without needing insulin injections or with significantly lower doses.  Read More

Children with type 1 diabetes at risk of acute kidney injury following DKA

A new study has found that children with type 1 diabetes (T1D) who are hospitalised for Diabetic Ketoacidosis (DKA) are more likely to develop acute kidney injury (AKI), a sudden episode of renal failure or damage. DKA is a severe complication that occurs with prolonged hyperglycaemia. It may occur at the initial presentation of newly diagnosed T1D or in someone with pre-existing T1D in times of illness or insulin omission.
Read More

First audit of national data from Australia’s unique registry highlights an urgent need to improve glycaemic control in young people with T1D.

International diabetes registries report that many young people with type 1 diabetes (T1D) do not meet their recommended targets for glycaemic control, however relevant Australian data has been lacking. The Australasian Diabetes Data Network (ADDN) funded by the Type 1 Diabetes Clinical Research Network (T1DCRN) and led by the Australasian Paediatric Endocrine Society (APEG) and Australian Diabetes Society (ADS) is a secure, centralised database that captures de-identified clinical data from thousands of people after diagnosis of T1D on a single purpose built database. The ADDN study group has published the first national surveillance of glycaemic control and management of type 1 diabetes in young people in Australia.

Read More

TEDDY project highlights benefit of being diagnosed before symptoms of type 1 diabetes appear

There are a number of genes linked to type 1 diabetes (T1D), but not everyone with genetic predisposition develops the condition. This suggests that there are likely environmental triggers that stimulate the development of T1D. The Environmental Determinants of Diabetes in the Young (TEDDY), a study part supported by JDRF, is a large prospective, longitudinal cohort study investigating the environmental factors that may contribute to T1D development.

vaccine

An article published by the TEDDY study group in Paediatric Diabetes this month highlights the benefits of early diagnosis of children at risk of T1D. Children involved in TEDDY are from six large clinical centres across the US and Europe and are being followed from birth until 15 years of age to track diet, illness, body growth and other life experiences.

Read More

T1DCRN awards $4.5 million in innovative research grants

Senator The Hon Simon Birmingham, Minister for Education and Training, and The Hon Greg Hunt MP, Minister for Health and Minister for Sport, have today announced the recipients of Innovation Award grants for research into type 1 diabetes.

Three bold, promising research projects have been selected and will benefit from $4.5 million in funding from the Type 1 Diabetes Clinical Research Network (T1DCRN), itself an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC).

imageedit_2_2405540522

In an exciting paradigm shift that aims to accelerate patient impact, the research funded by the Innovation Award grants will explore new directions in the search for a cure for type 1 diabetes, including concepts that have never before been investigated.

Read More